Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress
Go back to Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress| Patient Safety Technologies, Inc. (NASDAQ: PSTX) | Delayed: 2.00 -0.04 (1.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.04 | 52 Week High | $2.36 | |||
| Open | $2.05 | 52 Week Low | $1.10 | |||
| Day High | $2.16 | P/E | N/A | |||
| Day Low | $2.00 | EPS | $-0.10 | |||
| Volume | 518,825 | |||||
